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ABSTRACT (186 words) 21 
Monitoring SARS-CoV-2 genetic diversity is strongly indicated because diversifying 22 
selection may lead to the emergence of novel variants resistant to naturally acquired or 23 
vaccine-induced immunity. To date, most data on SARS-CoV-2 genetic diversity has 24 
come from the sequencing of clinical samples, but such studies may suffer limitations 25 
due to costs and throughput. Wastewater-based epidemiology may provide an 26 
alternative and complementary approach for monitoring communities for novel variants. 27 
Given that SARS-CoV-2 can infect the cells of the human gut and is found in high 28 
concentrations in feces, wastewater may be a valuable source of SARS-CoV-2 RNA, 29 
which can be deep sequenced to provide information on the circulating variants in a 30 
community. Here we describe a safe, affordable protocol for the sequencing of SARS-31 
CoV-2 RNA using high-throughput Illumina sequencing technology. Our targeted 32 
sequencing approach revealed the presence of mutations associated with several 33 
Variants of Concern at appreciable frequencies. Our work demonstrates that 34 
wastewater-based SARS-CoV-2 sequencing can inform surveillance efforts monitoring 35 
the community spread of SARS-CoV-2 Variants of Concern and detect the appearance 36 
of novel emerging variants more cheaply, safely, and efficiently than the sequencing of 37 
individual clinical samples.  38 
IMPORTANCE (140 words) 39 
The SARS-CoV-2 pandemic has caused millions of deaths around the world as 40 
countries struggle to contain infections. The pandemic will not end until herd immunity is 41 
reached, that is, when most of the population has either recovered from SARS-CoV-2 42 
infection or is vaccinated against SARS-CoV-2. However, the emergence of new SARS-43 
CoV-2 variants of concern threatens to erase gains. Emerging new variants may re-44 
infect persons who have recovered from COVID-19 or may evade vaccine-induced 45 
immunity. However, scaling up SARS-CoV-2 genetic sequencing to monitor Variants of 46 
Concern in communities around the world is challenging. Wastewater-based 47 
sequencing of SARS-CoV-2 RNA can be used to monitor the presence of emerging 48 
variants in large communities to enact control measures to minimize the spread of these 49 
variants. We describe here the identification of alleles associated with several variants 50 
of concern in wastewater obtained from NYC watersheds. 51 
KEYWORDS: coronavirus, environmental microbiology, Illumina sequencing, 52 
metagenomics, NGS, sewage, virus surveillance, Variants of Concern, wastewater-53 
based epidemiology 54 
INTRODUCTION 55 
The emergence of novel SARS-CoV-2 Variants of Concern, including B.1.1.7 from the 56 
United Kingdom and B.1.351 from South Africa, has provoked intense speculation about 57 
the future of the pandemic (1-3). Early studies suggest that these new variants may be 58 
more transmissible (4-6). Even more concerning are reports of decreased antibody-59 
mediated neutralization of these variants (7-9). Regardless of the biological attributes of 60 
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these novel variants, it is clear that behavioral interventions, public health measures, 61 
vaccinations, and reduced numbers of susceptible individuals will impose strong 62 
diversifying selection on SARS-CoV-2 to enhance transmission and/or evade host 63 
immunity (10). We should anticipate that the continued evolution of SARS-CoV-2 may 64 
result in variants that evade natural or vaccine-mediated immunity. As such, intensive 65 
monitoring of SARS-CoV-2 genetic diversity and evolution is vital to rapidly identify 66 
Variants of Concern as they emerge. 67 
Currently, most SARS-CoV-2 genetic surveillance is conducted via the genome 68 
sequencing of viral RNA obtained from clinical specimens. While occurring at a much 69 
greater rate and volume than previous epidemics, the sequencing of clinical specimens 70 
is limited by cost, coverage, quality, and throughput concerns. In developed countries, 71 
these issues are not readily apparent, but sequencing efforts in underdeveloped 72 
countries has been more restricted (11). Another disadvantage of focusing on clinical 73 
strains stems from the large number of asymptomatic or mildly symptomatic infections 74 
(12). SARS-CoV-2 sequencing efforts will suffer biases if genomic information is more 75 
frequently obtained from seriously ill patients, rather than from asymptomatic patients, 76 
and those with mild symptoms who choose to follow the CDC’s advice and convalesce 77 
at home. Wastewater-based epidemiology may provide an alternative and 78 
complementary approach to provide more representative SARS-CoV-2 genetic data at 79 
lower costs and higher throughput. 80 
Given that SARS-CoV-2 has been detected in fecal samples (13, 14), and subsequently 81 
in wastewater, wastewater is being monitored in communities around the world to 82 
determine SARS-CoV-2 prevalence in communities (15-17). Furthermore, isolation of 83 
SARS-CoV-2 RNA from wastewater coupled with high-throughput deep sequencing 84 
provides an almost unlimited source of unbiased viral sequences, which can be used to 85 
monitor frequencies of Variants of Concern in populations (18-20). We have focused on 86 
the use of targeted sequencing of the spike genomic region known to encode Variants 87 
of Concern. Our approach, while limited to a specific region of the genome, is 88 
affordable, rapid and generates sufficient coverage to quantify known variants and to 89 
identify possible emerging ones.   90 
Our team, in conjunction with the New York City Department of Environmental 91 
Protection, has been monitoring the genetic signal of SARS-CoV-2 in the wastewater of 92 
all 14 wastewater treatment plants in NYC, an area that encompasses a population of 93 
8,419,000 persons, since June 2020. We developed and optimized a protocol for safe, 94 
cost-effective, and repeatable quantitation of SARS-CoV-2 copy number by RT-qPCR 95 
(21). Our protocol performed strongly in a large-scale, nationwide comparative study of 96 
the reproducibility and sensitivity of 36 methods of quantifying SARS-CoV-2 in 97 
wastewater (22). Our protocol is identified as 4S.1(H) in Table 3. We further extended 98 
the utility of our protocol by deep sequencing SARS-CoV-2 RNA isolated from 99 
wastewater samples. Here we report presence of alleles associated with different 100 
Variants of Concern at appreciable frequencies. Our findings provide support for recent 101 
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observations of increasing frequencies of New York Variant of Interest B.1.526 in 102 
clinical samples (23, 24), as well as the presence of Variants of Concern from the 103 
United Kingdom, California, South Africa and Brazil (25). Furthermore, our results 104 
demonstrate the utility of wastewater-based epidemiology for the timely identification of 105 
novel variants of concern arising in communities.  106 
RESULTS AND DISCUSSION 107 
Targeted sequencing is a viable approach for identifying SARS-C0V-2 mutations. 108 
We generated cDNA from NYC wastewater samples that exhibited RT-qPCR Cts values 109 
ranging from 28 to 24 Cts corresponding to 26,443 and 1,423,339 N1 copies/L, 110 
respectively. Using this cDNA as a template, we PCR amplified a region of the receptor 111 
binding domain (RBD) of the SARS-CoV-2 Spike gene, spanning amino acid residues 112 
P410 to L513, which encompasses mutations that are found in several known Variants 113 
of Concern. A total of 420 single nucleotide variants were identified in the 45 samples 114 
sequenced (Supplementary Table 1). Coverage ranged from 1,037x – 118,737x with a 115 
mean of 23,586x (Supplementary Table 1). Across all samples, we identified 75 unique 116 
mutations resulting in amino acid substitutions, 20 unique synonymous mutations, and 117 
18 deletions resulting in a frameshift, in the 332 bp region targeted (Supplementary 118 
Table 1).  119 
Mutations associated with Variants of Concern are present in NYC wastewater. 120 
The five mutations found at highest frequencies, both in terms of frequency of reads 121 
within samples and found in the most samples, were L452R, E484K, N501Y, S494P, 122 
and S477N. All five mutations are associated with known Variants of Concern (Fig. 1; 123 
Supplementary Table 2). On Jan 31st, we sequenced samples from two wastewater 124 
treatment plants in NYC and identified reads containing mutations L452R, S477N, 125 
E484K, S494P and N501Y in both. On February 28th and March 14th samples from all 126 
14 wastewater treatment plants in NYC were sequenced, revealing the presence of a 127 
high proportion of reads containing mutations L452R, S477N, E484K, S494P and 128 
N501Y (Fig. 1). Mutation L452R is unique to Pango lineage Variants of Concern 129 
B.1.427 and B.1.429, which were first observed in California (25, 26). Mutation S477N is 130 
only found in New York Variant of Interest B.1.526 (23-25, 27). Mutation E484K has 131 
been reported in Variants of Concern B.1.1.7 from the United Kingdom, P.1 and P.2 132 
from Brazil, and B.1.351 from South Africa, and B.1.525 and B.1.526 from New York 133 
(25). Mutation S494P is only found in Variant of Concern B.1.1.7 from the United 134 
Kingdom (25). Mutation N501Y is found in Variants of Concern B.1.1.7 from the United 135 
Kingdom, P.1 from Brazil, and B.1.351 from South Africa (25). 136 
The finding that unique mutations associated with different Variants of Concern in our 137 
pooled sequencing assay suggests the circulation of these variants in NYC. A caveat 138 
with our approach, however, is that we cannot conclusively identify the presence of a 139 
Variant of Concern since our sequencing assay targets only a region of the receptor 140 
binding domain, and some significant mutations are outside the sequenced region. 141 
Furthermore, additional mutations occurring in the primer binding region may allow 142 
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some mutations to go undetected because their DNA could not be amplified. We are 143 
expanding our targeted sequencing approach to include additional regions of interest to 144 
minimize the chance of missing important variants. Additionally, we intend to generate 145 
cDNA with random hexamers, and to incorporate a level of degeneracy in the 146 
sequencing primers to increase the breadth of our targeted sequencing.  147 
Our most recent data from March 14th suggests a slight decrease in the prevalence of 148 
the E484K variant, but we cannot draw firm conclusions due to the nature of our 149 
sequencing assay, which relies on the collective sequencing of a large pool of 150 
individuals. Nevertheless, our frequency data agrees with that recently observed in 151 
human clinical samples from NYC (23, 24, 27). We intend to supplement our targeted 152 
sequencing approach with whole genome amplicon sequencing in the future.  153 
We believe that our approach offers a viable alternative to whole genome sequencing 154 
for the detection of known variants and can be rapidly deployed to detect additional 155 
emerging variants of concern. Importantly as a cost saving measure, labs can generate 156 
the libraries themselves and outsource the sequencing component to companies/core 157 
facilities if they lack access to a sequencer, generally with a short turnaround time.     158 
MATERIALS AND METHODS 159 
Wastewater Sample Processing and RNA Extraction. Wastewater was collected 160 
from 14 NYC wastewater treatment plants and RNA isolated according to our previously 161 
published protocol (dx.doi.org/10.17504/protocols.io.brr6m59e) (21). Control SARS-162 
CoV-2 synthetic RNA was purchased from Twist Bioscience (#102019).  163 
Briefly, 250 mL from 24-hr composite raw sewage samples were obtained from NYC 164 
wastewater treatment plants (WWTPs) and centrifuged at 5,000 x g for 10 min at 4℃ to 165 
pellet solids. 40 mL of supernatant was passed through a 0.22 μM filter. Filtrate was 166 
stored at 4℃ for 24 hrs after adding 0.9 g sodium chloride and 4.0 g PEG 8000 (Fisher) 167 
then centrifuged at 12,000 x g for 120 minutes at 4 °C to pellet precipitate. The pellet 168 
was resuspended in 1.5 mL TRIzol (Fisher), and RNA was purified according to the 169 
manufacturer’s instructions.  170 
Targeted PCR. Our target for sequencing was a 332 bp region of the Receptor Binding 171 
Domain (RBD) of the spike protein spanning amino acid residues P420 to L513. 172 
Mutations in this region are of critical importance as they might help the variants evade 173 
current antibody treatments and vaccines. RNA isolated from wastewater was used to 174 
generate cDNA using ProtoScript® II Reverse Transcriptase (New England Biolabs). 175 
The RNA was incubated with an RBD specific primer (ccagatgattttacaggctgcg) and 176 
dNTPs (0.5 mM final concentration) at 65℃ for 5 minutes and placed on ice. The RT 177 
buffer, DTT (0.01 M final concentration), and the RT were added to the same tube and 178 
incubated at 42℃ for 2 hours followed by 20 minutes at 65℃ to inactivate the enzyme. 179 
The RBD region was amplified using Q5® High-Fidelity DNA Polymerase using the 180 
forward primer 5’ -181 
TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGccagatgattttacaggctgcg-3’ and 182 
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reverse primer 5’-183 
GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGgaaagtactactactctgtatggttgg-3’, 184 
which incorporate Illumina adaptors. PCR performed as follows: 98℃ for 30 seconds, 185 
followed by 40 cycles of 98℃ 5 seconds, 53℃ for 15 seconds and 65℃ for 1 minute and 186 
a final extension at 65℃ for 1 minute.  187 
Targeted Sequencing. The RBD amplicons were purified using AMPure XP beads 188 
(Beckman Coulter). Index PCR was performed using the Nextera DNA CD Indexes kit 189 
(Illumina) with 2X KAPA HiFi HotStart ReadyMix (Roche), and indexed PCR products 190 
purified using AMPure beads. The indexed libraries were quantified using the Qubit 3.0 191 
and Qubit dsDNA HS Assay Kit and diluted in 10 mM Tris-HCl to a final concentration of 192 
approximately 0.3 ng/μL (1 nM). The libraries were pooled together and diluted to a final 193 
concentration of 50 pM. Before sequencing on an Illumina iSeq100, a 10% spike-in of 194 
50 pM PhiX control v3 (Illumina) was added to the pooled library.  195 
Bioinformatics. Sequencing data was uploaded to the BaseSpace Sequence Hub, and 196 
the reads demultiplexed using a FASTQ generation script. Reads were processed using 197 
the published Geneious workflows for preprocessing of NGS reads and assembly of 198 
SARS-CoV-2 amplicons (https://help.geneious.com/hc/en-us/articles/360045070991-199 
Assembly-of-SARS-CoV-2-genomes-from-tiled-amplicon-Illumina-sequencing-using-200 
Geneious-Prime and https://help.geneious.com/hc/en-us/articles/360044626852-Best-201 
practice-for-preprocessing-NGS-reads-in-Geneious-Prime). Paired reads were trimmed, 202 
and the adapter sequences removed with the BBDuk plugin. Trimmed reads were 203 
merged and aligned to the SARS-CoV-2 reference genome MN908947. Variants were 204 
called using the Annotate and Predict Find Variations/SNPs in Geneious and verified by 205 
using the V-PIPE SARS-CoV-2 application (https://cbg-ethz.github.io/V-pipe/sars-cov-206 
2/)(28).  207 
Data Availability 208 
Raw sequencing reads are available in NCBI’s Sequence Read Archive (SRA) under 209 
accession # PRJNA715712.  210 
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FIGURE LEGEND 224 
Figure 1. Frequencies of reads associated with five selected mutations associated with 225 
SARS-CoV-2 Variants of Concern from wastewater obtained from 14 NYC wastewater 226 
treatment plants on two separate dates.  227 
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